ATE454455T1 - Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung - Google Patents
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellungInfo
- Publication number
- ATE454455T1 ATE454455T1 AT06719694T AT06719694T ATE454455T1 AT E454455 T1 ATE454455 T1 AT E454455T1 AT 06719694 T AT06719694 T AT 06719694T AT 06719694 T AT06719694 T AT 06719694T AT E454455 T1 ATE454455 T1 AT E454455T1
- Authority
- AT
- Austria
- Prior art keywords
- guiding
- production
- heterologous
- polypeptides
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64701305P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/002951 WO2006081430A2 (en) | 2005-01-27 | 2006-01-27 | Leader sequences for directing secretion of polypeptides and methods for production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454455T1 true ATE454455T1 (de) | 2010-01-15 |
Family
ID=36741080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06719694T ATE454455T1 (de) | 2005-01-27 | 2006-01-27 | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080286834A1 (de) |
| EP (1) | EP1841874B1 (de) |
| JP (2) | JP2008528033A (de) |
| AT (1) | ATE454455T1 (de) |
| AU (1) | AU2006207999A1 (de) |
| CA (1) | CA2589895A1 (de) |
| DE (1) | DE602006011574D1 (de) |
| DK (1) | DK1841874T3 (de) |
| WO (1) | WO2006081430A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006272759B2 (en) | 2005-07-22 | 2012-01-12 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| CA2621363C (en) | 2005-09-13 | 2015-07-07 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| WO2008073660A1 (en) * | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2009056330A1 (en) * | 2007-10-31 | 2009-05-07 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| CN102083456B (zh) * | 2008-03-25 | 2015-12-02 | 阿姆拉特斯治疗公司 | 神经退行性障碍 |
| FR2933773B1 (fr) * | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| JP5787757B2 (ja) | 2008-08-04 | 2015-09-30 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質 |
| WO2010075194A1 (en) * | 2008-12-22 | 2010-07-01 | St. Jude Children's Research Hospital | Prokaryotic expression of soluble, active dkk |
| JP2010183885A (ja) * | 2009-02-13 | 2010-08-26 | Kobe Univ | タンパク質の製造方法およびそれに用いる発現ベクター |
| EP2478003A4 (de) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | Haarwuchsverfahren unter verwendung extrazellulärer fgfr4-domänen |
| WO2011060333A1 (en) | 2009-11-13 | 2011-05-19 | Five Prime Therapeutics, Inc. | Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2 |
| CA2928846A1 (en) | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| EP2566517B1 (de) | 2010-05-04 | 2018-10-24 | Five Prime Therapeutics, Inc. | Csf1r-bindende antikörper |
| DK2585098T3 (da) | 2010-06-28 | 2014-11-03 | Five Prime Therapeutics Inc | Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser |
| EP2444495A1 (de) * | 2010-10-20 | 2012-04-25 | Algenics | Sekretion rekombinanter Polypeptide im extrazellularen Medium eines Diatoms |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| EA025828B1 (ru) | 2010-11-15 | 2017-02-28 | Файв Прайм Терапьютикс, Инк. | Комбинированная терапия внеклеточным доменом fgfr1 |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| EP2663578A2 (de) | 2011-01-14 | 2013-11-20 | Five Prime Therapeutics, Inc. | Il-27 antagonisten zur behandlung von entzündungserkrankungen |
| WO2013074492A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| CN104159611A (zh) | 2012-02-22 | 2014-11-19 | 阿莱斯亚生物疗法股份有限公司 | 共使用簇集蛋白抑制剂和egfr抑制剂以治疗癌症 |
| BR112014028013A2 (pt) | 2012-05-11 | 2018-02-27 | Five Prime Therapeutics Inc | métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| KR20150047593A (ko) | 2012-08-31 | 2015-05-04 | 파이브 프라임 테라퓨틱스, 인크. | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 |
| US20150366997A1 (en) | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
| WO2014152940A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| HUE058243T2 (hu) | 2013-08-01 | 2022-07-28 | Five Prime Therapeutics Inc | Afukozilált, FGFR2IIIB elleni antitestek |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| SG11201702723VA (en) | 2014-10-29 | 2017-05-30 | Five Prime Therapeutics Inc | Combination therapy for cancer |
| CA2969341C (en) | 2014-12-22 | 2023-07-04 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
| WO2016154177A2 (en) | 2015-03-23 | 2016-09-29 | Jounce Therapeutics, Inc. | Antibodies to icos |
| WO2016168149A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CN108350505A (zh) | 2015-10-22 | 2018-07-31 | 震动疗法股份有限公司 | 用于测定icos表达的基因标志 |
| CN115975044A (zh) | 2016-04-25 | 2023-04-18 | 戊瑞治疗有限公司 | 用于治疗病理性肌肉损失和虚弱的nope |
| AR110017A1 (es) | 2016-11-02 | 2019-02-13 | Jounce Therapeutics Inc | Anticuerpos de pd-1 y usos de estos |
| WO2018144097A1 (en) | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
| JP2020504756A (ja) * | 2016-12-29 | 2020-02-13 | ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | タンパク質薬物のｉｎ ｖｉｖｏ半減期延長のためのキニノーゲン−１由来ペプチド |
| US20200031944A1 (en) | 2017-03-31 | 2020-01-30 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| CA3065540A1 (en) | 2017-06-06 | 2018-12-13 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
| CA3087166A1 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies to lilrb2 |
| AU2019302454A1 (en) | 2018-07-09 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to ILT4 |
| EP4103285A2 (de) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antikörper und fusionsproteine, die an ccr8 binden, und deren verwendungen |
| EP4114931A4 (de) * | 2020-03-05 | 2024-05-01 | Curie Co Inc | Verfahren zur zellfreien proteinexpression von reifen polypeptiden aus zymogenen und proproteinen |
| US20230303695A1 (en) | 2020-08-10 | 2023-09-28 | Tengfei XIAO | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
| DE1105508T1 (de) * | 1998-08-17 | 2002-02-21 | Europ Lab Molekularbiolog | Verfahren zur reinigung von proteinen und biomolekül- oder proteinkomplexen |
| WO2005082934A2 (en) * | 2004-02-20 | 2005-09-09 | Five Prime Therapeutics, Inc. | Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use |
| US20070264277A1 (en) * | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
-
2006
- 2006-01-27 JP JP2007553266A patent/JP2008528033A/ja active Pending
- 2006-01-27 AT AT06719694T patent/ATE454455T1/de not_active IP Right Cessation
- 2006-01-27 US US11/883,065 patent/US20080286834A1/en not_active Abandoned
- 2006-01-27 CA CA002589895A patent/CA2589895A1/en not_active Abandoned
- 2006-01-27 EP EP06719694A patent/EP1841874B1/de not_active Not-in-force
- 2006-01-27 AU AU2006207999A patent/AU2006207999A1/en not_active Abandoned
- 2006-01-27 DE DE602006011574T patent/DE602006011574D1/de active Active
- 2006-01-27 WO PCT/US2006/002951 patent/WO2006081430A2/en active Application Filing
- 2006-01-27 DK DK06719694.9T patent/DK1841874T3/da active
-
2009
- 2009-01-19 JP JP2009009381A patent/JP2009131268A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006081430A2 (en) | 2006-08-03 |
| CA2589895A1 (en) | 2006-08-03 |
| EP1841874B1 (de) | 2010-01-06 |
| DK1841874T3 (da) | 2010-05-17 |
| WO2006081430A9 (en) | 2006-11-30 |
| WO2006081430A3 (en) | 2007-04-05 |
| JP2009131268A (ja) | 2009-06-18 |
| AU2006207999A1 (en) | 2006-08-03 |
| JP2008528033A (ja) | 2008-07-31 |
| EP1841874A2 (de) | 2007-10-10 |
| DE602006011574D1 (de) | 2010-02-25 |
| US20080286834A1 (en) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454455T1 (de) | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung | |
| ATE478145T1 (de) | Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren | |
| ATE449109T1 (de) | Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung | |
| ATE424458T1 (de) | Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung | |
| WO2006053021A3 (en) | Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby | |
| CY1112334T1 (el) | Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων | |
| WO2005071088A3 (en) | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof | |
| DE602005009738D1 (de) | Verfahren zur herstellung und sekretion modifizierter peptide | |
| DK1609863T3 (da) | Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse | |
| ATE448312T1 (de) | Leitsequenzen zur verwendung bei der produktion von proteinen | |
| DE60026733D1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
| EP4302824A3 (de) | Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden | |
| ATE374819T1 (de) | Antagonistischer antikörper gegen pro842 | |
| DE60117641D1 (de) | Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide | |
| DK1300417T3 (da) | Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor | |
| DE69926415D1 (de) | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren | |
| DK1591452T3 (da) | Secernerede og transmembrane polypeptider og nukleinsyrer kodende for samme | |
| ATE489463T1 (de) | Polypeptid mit einer delta-5-fettsäure- desaturierungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon. | |
| DE60043242D1 (de) | Ausgeschiedene und transmembrane Polypeptide und dafür kodierende Nukleinsäure | |
| ATE363537T1 (de) | Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure | |
| DE69930422D1 (de) | Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |